Rocuronium bromide and organ function.
Neuromuscular blocking drugs can be divided into those that are: (i) excreted entirely by the kidney; (ii) predominantly by the kidney but also by the liver; (iii) mainly by the liver but also by the kidney or; (iv) removed by other metabolic pathways. Rocuronium is mainly excreted by the liver and pharmacokinetic and pharmacodynamic studies in humans suggest that its duration of action may be prolonged to a greater extent in patients with hepatic disease than in patients with renal disease. The effect is likely to be modest and not a contra-indication to its use.
Bevan
D R
DR
University of British Columbia, Faculty of Medicine, Department of Anaesthesia, Vancouver, Canada.
D000732:Androstanols / Q000493:pharmacokinetics*; D000818:Animals; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008107:Liver Diseases / Q000378:metabolism; D003473:Neuromuscular Nondepolarizing Agents / Q000493:pharmacokinetics*; D051437:Renal Insufficiency / Q000378:metabolism; D000077123:Rocuronium
D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D000077123:Rocuronium